Stocks in play: Knight Therapeutics Inc.
And Sumitomo Pharma America Inc. announced today that Knight and SMPA’s affiliates have entered into exclusive license and supply agreements to commercialize MYFEMBREE® (relugolix/estradiol/norethindrone acetate), ORGOVYX® (relugolix) and vibegron in Canada, as well as an asset purchase agreement under which Knight will acquire certain mature products (the “Mature Products”, together with MYFEMBREE®, ORGOVYX® and vibegron, the “Products”). For the year ended March 2025, the Products generated $11.2 million in revenue. Knight Therapeutics Inc. shares T.GUD are trading unchanged at $5.82.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.